Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (Q2)Jan 31, 2026 | (Q1)Oct 31, 2025 | (FY)Jul 31, 2025 | (Q4)Jul 31, 2025 | (Q3)Apr 30, 2025 | (Q2)Jan 31, 2025 | (Q1)Oct 31, 2024 | (FY)Jul 31, 2024 | (Q4)Jul 31, 2024 | (Q3)Apr 30, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -136.03%-430.12K | -124.22%-19.61K | 92.20%-164.61K | 88.44%-82.82K | 106.26%19.46K | 77.02%-182.23K | 127.86%80.98K | -7.55%-2.11M | -22.84%-716.31K | 16.10%-310.69K |
| Net income from continuing operations | 29.29%-144.07K | 56.03%-85.04K | -21.21%-2.67M | -89.25%-1.37M | -152.59%-899.7K | 69.68%-203.73K | 56.84%-193.39K | 80.25%-2.2M | 91.78%-723.82K | 14.71%-356.19K |
| Operating gains losses | 38.76%-19.65K | 114.67%11.51K | 27.11%-11.51K | -80.59%23.41K | 189.44%75.63K | 42.05%-32.08K | -2,347.98%-78.48K | -678.01%-15.8K | 336.90%120.63K | -505.43%-84.56K |
| Depreciation and amortization | -31.10%11.26K | -10.37%14.65K | 0.00%65.39K | -7.43%16.35K | 8.73%16.35K | 0.01%16.35K | 0.00%16.35K | 309.57%65.39K | 20.53%17.66K | 3,332.88%15.04K |
| Asset impairment expenditure | --0 | --0 | 664.22%1.93M | 346.24%1.13M | --759.9K | --44.52K | --0 | -96.95%252.97K | --252.97K | --0 |
| Remuneration paid in stock | --0 | --0 | -95.72%10.27K | --0 | --0 | --0 | -86.36%10.27K | -83.07%239.63K | -76.80%50.5K | 190.85%42.9K |
| Other non cashItems | -754.95%-19.99K | -139.82%-4.49K | 20.05%9.17K | -354.48%-7.33K | -29.78%2.17K | -7.66%3.05K | 786.07%11.28K | --7.64K | --2.88K | --3.1K |
| Change In working capital | -2,392.08%-257.68K | -86.11%43.76K | 207.57%495.45K | 128.76%125.72K | -5.67%65.11K | 93.39%-10.34K | 392.59%314.95K | 17.70%-460.6K | -65.85%-437.15K | -36.12%69.02K |
| -Change in receivables | -179.01%-20.87K | -85.47%26.22K | 315.27%221.95K | 154.33%14.13K | 101.95%941 | 72.65%26.41K | 509.40%180.47K | -6,070.06%-103.1K | -163.27%-26.01K | -3,309.46%-48.31K |
| -Change in prepaid assets | 354.23%58.76K | -122.04%-17.76K | 115.84%62.33K | 113.48%44.75K | -2,549.79%-39.91K | 72.57%-23.11K | 279.03%80.6K | -1,125.72%-393.47K | -1,136.58%-332.1K | 63.23%1.63K |
| -Change in payables and accrued expense | -2,067.45%-295.58K | -34.49%35.3K | 487.07%211.16K | 184.56%66.84K | -10.05%104.08K | 84.41%-13.64K | -37.89%53.88K | 106.80%35.97K | 71.55%-79.05K | 6.66%115.71K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -136.03%-430.12K | -124.22%-19.61K | 92.20%-164.61K | 88.44%-82.82K | 106.26%19.46K | 77.02%-182.23K | 127.86%80.98K | -7.55%-2.11M | -22.84%-716.31K | 16.10%-310.69K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -108.46%-515.28K | 50.33%-208.48K | 78.35%-780.03K | 98.96%-7.54K | 83.84%-105.6K | 75.29%-247.18K | 65.82%-419.72K | -41.52%-3.6M | -35.82%-721.8K | 15.71%-653.29K |
| Net PPE purchase and sale | -156.69%-237.94K | 50.33%-208.48K | 78.35%-780.03K | 98.96%-7.54K | -18.25%-772.5K | 141.95%419.72K | 65.82%-419.72K | -41.52%-3.6M | -35.82%-721.8K | 15.71%-653.29K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -108.46%-515.28K | 50.33%-208.48K | 78.35%-780.03K | 98.96%-7.54K | 83.84%-105.6K | 75.29%-247.18K | 65.82%-419.72K | -41.52%-3.6M | -35.82%-721.8K | 15.71%-653.29K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 30,233.34%2.23M | 30.39%-5.04K | -101.50%-29.48K | -2.33%-7.41K | -100.37%-7.41K | -2.29%-7.41K | -420.55%-7.25K | -72.77%1.97M | 74.83%-7.24K | -71.67%1.98M |
| Net issuance payments of debt | -151.50%-12.54K | 25.44%-3.42K | -119.68%-20.31K | -26.26%-5.51K | -26.27%-5.24K | -26.21%-4.98K | -242.64%-4.58K | -896.34%-9.25K | -369.94%-4.36K | ---4.15K |
| Net common stock issuance | ---- | ---- | --0 | --0 | ---- | ---- | ---- | -71.43%2M | --0 | ---- |
| Cash dividends paid | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- |
| Interest paid (cash flow from financing activities) | 45.03%-2.67K | 38.83%-3.25K | 27.94%-18.33K | 33.82%-3.81K | 29.73%-4.35K | 26.35%-4.85K | 22.97%-5.32K | ---25.44K | ---5.76K | ---6.19K |
| Net other financing activities | -80.29%478 | -38.77%1.63K | 3,126.06%9.16K | -33.78%1.91K | 126.54%2.17K | -26.34%2.43K | 15.47%2.66K | 100.87%284 | 110.34%2.88K | ---8.19K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 30,233.34%2.23M | 30.39%-5.04K | -101.50%-29.48K | -2.33%-7.41K | -100.37%-7.41K | -2.29%-7.41K | -420.55%-7.25K | -72.77%1.97M | 74.83%-7.24K | -71.67%1.98M |
| Net cash flow | ||||||||||
| Beginning cash position | -93.68%58.07K | -76.99%291.2K | -74.76%1.27M | -85.65%388.97K | -71.50%482.53K | -73.69%919.35K | -74.76%1.27M | 117.54%5.01M | -55.98%2.71M | 450.45%1.69M |
| Current changes in cash | 394.81%1.29M | 32.62%-233.14K | 74.01%-974.13K | 93.24%-97.77K | -109.19%-93.56K | 75.74%-436.82K | 77.24%-345.98K | -238.37%-3.75M | -26.41%-1.45M | -82.61%1.02M |
| End cash Position | 178.92%1.35M | -93.68%58.07K | -76.99%291.2K | -76.99%291.2K | -85.65%388.97K | -71.50%482.53K | -73.69%919.35K | -74.76%1.27M | -74.76%1.27M | -55.98%2.71M |
| Free cash from | -382.81%-671.64K | 32.66%-228.09K | 83.47%-944.64K | 93.73%-90.36K | 21.88%-753.04K | 113.24%237.49K | 77.69%-338.73K | -26.78%-5.72M | -29.20%-1.44M | 15.83%-963.98K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.